Formulation and manufacturability of biologics

Current Opinion in Biotechnology

Volumn 20, Issue 6, 2009, Pages 708-714

  Shire, Steven J ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DOSE; MANUFACTURABILITY; MANUFACTURING PROCESS; PROTEIN AGGREGATION; PROTEIN CONCENTRATIONS; UNIT OPERATION;

DRUG DOSAGE; INDUSTRIAL ENGINEERING; MONOCLONAL ANTIBODIES; PRODUCTION ENGINEERING; PROTEINS;

MANUFACTURE;

DISACCHARIDE; MANNITOL; MONOCLONAL ANTIBODY; SORBITOL; SUCROSE; TREHALOSE;

BIOLOGICAL THERAPY; CONCENTRATION (PARAMETERS); CONTAINER; DIAFILTRATION; DRUG DEGRADATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; FREEZE DRYING; FREEZING; GEL PERMEATION CHROMATOGRAPHY; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; SPRAY DRYING; THAWING; THERMOSTABILITY; ULTRAFILTRATION; VISCOSITY;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOPHARMACEUTICS; BIOTECHNOLOGY; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG DESIGN; DRUG PACKAGING; DRUG STABILITY; DRUG STORAGE; HUMANS; PRESSURE; PROTEINS;

EID: 70449704158     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2009.10.006     Document Type: Review

References (65)

1. Genovesi C.S. Several uses for tangential-flow filtration in the pharmaceutical industry. J Parenter Sci Technol 37 (1983) 81-86
2. Shiloach J., Martin N., and Moes H. Tangential flow filtration. Adv Biotechnol Process 8 (1988) 97-125
3. van Reis R., and Zydney A. Membrane separations in biotechnology. Curr Opin Biotechnol 12 (2001) 208-211
4. Shire S.J., Shahrokh Z., and Liu J. Challenges in the development of high protein concentration formulations. [Review]. J Pharm Sci 93 (2004) 1390-1402. This paper discusses many of the challenges in the development and manufacturing of high protein concentration formulations. Additional data, are presented on the method to prepare lyophilized formulations for SC delivery after reconstitution.
5. Thomas C.R., and Dunnill P. Action of shear on enzymes: studies with catalase and urease. Biotechnol Bioeng 21 (1979) 2279-2302
6. Thomas C.R., Nienow A.W., and Dunnill P. Action of shear on enzymes: studies with alcohol dehydrogenase. Biotechnol Bioeng 21 (1979) 2263-2278
7. Watterson J.G., Schaub M.C., and Waser P.G. Shear-induced protein-protein interaction at the air-water interface. Biochim Biophys Acta 356 (1974) 133-143
8. Bee J.S., Stevenson J.L., Mehta B., Svitel J., Pollastrini J., Platz R., Freund E., Carpenter J.F., and Randolph T.W. Response of a concentrated monoclonal antibody formulation to high shear. Biotechnol Bioeng 103 (2009) 936-943
9. Liu J, Shire SJ: High concentration antibody and protein formulations. US Patent Oct. 13, 2006, US20070053900 A1.
10. Liu J, Shire SJ: Reduced-viscosity concentrated protein formulations. US Patent Dec. 15, 2006, US20070116700 A1. This patent discusses excipients that have been used to prepare high concentration liquid formulations with low viscosity.
11. Kanai S., Liu J., Patapoff T.W., and Shire S.J. Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity. J Pharm Sci 97 (2008) 4219-4227
12. Liu J., Nguyen M.D.H., Andya J.D., and Shire S.J. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci 94 (2005) 1928-1940. This is the first study that shows a linkage between reversible self-association of a MAb and its high viscosity. The studies compare self-association and viscosity of three closely related MAbs that have the same IgG1 human Fc framework, but different variable binding domains (generally referred to as complementarity determining regions or CDRs).
13. Winter C: Process for concentration of antibodies and therapeutic products. US Patent Feb. 19, 2009, US20090214522 A1. The modification of tangential-flow filtration (TFF) processing for high concentration formulations using high temperature to lower viscosity is discussed.
14. Winter C., Mulherkar B., Thai B., Liu J., Kanai S., and Shire S. Formulation strategy and high temperature UF to achieve high concentration rhuMAbs. Presented at Recovery of Biological Products XIII. Quebec City, Canada (2008)
15. Singh S.K., Rathore N., McAuley A., and Rathore A.S. Best practices for formulation and manufacturing of biotech drug products. BioPharm 22 (2009) 32-48. Nice review that focuses on technology for freezing large volumes of drug substance.
16. Bodis A., Benkoczy Z., Gondar E., Illes J., and Neszmelyi E. Filtration of solutions with high viscosity: from laboratory experiments to production. Acta Pharm Hung 68 (1998) 127-132
17. Aranha H., and Meeker J. Microbial retention characteristics of 0.2-microns-rated nylon membrane filters during filtration of high viscosity fluids at high differential pressure and varied temperatures. PDA J Pharm Sci Technol 49 (1995) 67-70
18. Bhatnagar B.S., Bogner R.H., and Pikal M.J. Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol 12 (2007) 505-523
19. Carpenter J.F., Chang B.S., Garzon-Rodriguez W., and Randolph T.W. Rational design of stable lyophilized protein formulations: theory and practice. Pharm Biotechnol 13 (2002) 109-133
20. Strambini G.B., and Gabellieri E. Proteins in frozen solutions: evidence of ice-induced partial unfolding. Biophys J 70 (1996) 971-976
21. Schwegman J.J., Carpenter J.F., and Nail S.L. Evidence of partial unfolding of proteins at the ice/freeze-concentrate interface by infrared microscopy. J Pharm Sci 98 (2009) 3239-3246
22. Webb S.D., Webb J.N., Hughes T.G., Sesin D.F., and Kincaid A.C. Freezing bulk-scale biopharmaceuticals using common techniques - and the magnitude of freeze-concentration. Biopharm 15 (2002) 2-8
23. Mattern M., Winter G., Kohnert U., and Lee G. Formulation of proteins in vacuum-dried glasses. II. Process and storage stability in sugar-free amino acid systems. Pharm Dev Technol 4 (1999) 199-208
24. Carpenter J.F., Pikal M.J., Chang B.S., and Randolph T.W. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res 14 (1997) 969-975. This is an excellent paper that provides a review of freeze-drying of proteins with specific practical advice on the type of excipients to choose and which to avoid.
25. Cleland J.L., Lam X., Kendrick B., Yang J., Yang T.H., Overcashier D., Brooks D., Hsu C., and Carpenter J.F. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. J Pharm Sci 90 (2001) 310-321
26. Izutsu K., Yoshioka S., and Terao T. Decreased protein-stabilizing effects of cryoprotectants due to crystallization. Pharm Res 10 (1993) 1232-1237
27. Izutsu K., Yoshioka S., and Terao T. Effect of mannitol crystallinity on the stabilization of enzymes during freeze-drying. Chem Pharm Bull 42 (1994) 5-8
28. Izutsu K.-I., and Kojima S. Excipient crystallinity and its protein-structure-stabilizing effect during freeze-drying. J Pharm Pharmacol 54 (2002) 1033-1039
29. Piedmonte D.M., Summers C., McAuley A., Karamujic L., and Ratnaswamy G. Sorbitol crystallization can lead to protein aggregation in frozen protein formulations. Pharm Res 24 (2007) 136-146
30. Lea C.H., and Hannan R.S. Studies of the reaction between proteins and reducing sugars in the 'dry' state. III. Nature of the protein groups reacting. Biochim Biophys Acta 5 (1950) 433-454
31. Ledesma-Osuna A.I., Ramos-Clamont G., and Vazquez-Moreno L. Characterization of bovine serum albumin glycated with glucose, galactose and lactose. Acta Biochim Pol 55 (2008) 491-497
32. Gadgil H.S., Bondarenko P.V., Pipes G., Rehder D., McAuley A., Perico N., Dillon T., Ricci M., Treuheit M., Gadgil H.S., et al. The LC/MS analysis of glycation of IgG molecules in sucrose containing formulations. J Pharm Sci 96 (2007) 2607-2621
33. Townsend M.W., and DeLuca P.P. Use of lyoprotectants in the freeze-drying of a model protein, ribonuclease A. [erratum appears in J Parenter Sci Technol 1989;43(1):47]. J Parenter Sci Technol 42 (1988) 190-199
34. Lueckel B., Helk B., Bodmer D., and Leuenberger H. Effects of formulation and process variables on the aggregation of freeze-dried interleukin-6 (IL-6) after lyophilization and on storage. Pharm Dev Technol 3 (1998) 337-346
35. Tang X.C., and Pikal M.J. Measurement of the kinetics of protein unfolding in viscous systems and implications for protein stability in freeze-drying. Pharm Res 22 (2005) 1176-1185
36. Kim H.J., Kim J.H., Youn S.H., and Shin C.S. Eutectic formation analysis of amino acid mixtures using molecular dynamics simulations. Biotechnol Progr 21 (2005) 1307-1314
37. Laitinen T. Localized corrosion of stainless steel in chloride, sulfate and thiosulfate containing environments. Corros Sci 42 (2000) 421-441
38. Lam X.M., Yang J.Y., and Cleland J.L. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J Pharm Sci 86 (1997) 1250-1255
39. Bennan J., Bing F., Boone H., Fernandez J., Miller D., Seely B., and van Deinse H. Evaluation of extractables from product-contact surfaces. Biopharm 15 (2002) 22-33
40. Yu X., Wood D., and Ding X. Extractables and leachables study approach for disposable materials used in bioprocessing. Biopharm 21 (2008) 42-51
41. Chang L.Q., and Pikal M.J. Mechanisms of protein stabilization in the solid state. [Review]. J Pharm Sci 98 (2009) 2886-2908. A very up-to-date recent review that discusses the major degradation pathways that occur in lyophilized protein formulations. This paper also focuses on what is currently known about the mechanisms of protein stabilization in the solid state.
42. Gupta R.I. Freeze-drying of proteins: some emerging concerns. [Review]. Biotechnol Appl Biochem 39 (2004) 165-177
43. Tang X.L., and Pikal M.J. Design of freeze-drying processes for pharmaceuticals: practical advice. [Review]. Pharm Res 21 (2004) 191-200
44. Wang W. Lyophilization and development of solid protein pharmaceuticals. [Review]. Int J Pharm 203 (2000) 1-60
45. Masters K. Spray Drying Handbook. edn 4 (1985), John Wiley & Sons, New York
46. Abdul-Fattah A.M., LKalcinia D.S., and Pikal M.J. The challenge of drying method selection for protein pharmaceuticals: product quality implications. [Review]. J Pharm Sci 96 (2007) 1886-1916
47. Moran A., and Buckton G. Adjusting and understanding the properties and crystallisation behaviour of amorphous trehalose as a function of spray drying feed concentration. Int J Pharm 341 (2007) 12-17
48. Forbes R.T., Barry B.W., and Elkordy A.A. Preparation and characterisation of spray-dried and crystallised trypsin: FT-Raman study to detect protein denaturation after thermal stress. Eur J Pharm Biopharm 30 (2007) 315-323
49. Liao Y.H., Brown M.B., Nazir T., Quader A., and Martin G.P. Effects of sucrose and trehalose on the preservation of the native structure of spray-dried lysozyme. Pharm Res 19 (2002) p1847-1853
50. Broadhead J., Rouan S.K., and Rhodes C.T. Spray drying of pharmaceuticals. Drug Dev Ind Pharm 18 (1992) p1169-1206
51. Wang H.E., and Wang Y.J. Peroxide formation in polysorbate 80 and protein stability. J Pharm Sci 91 (2002) 2252-2264
52. Hora M.S., Rana R.K., Wilcox C.L., Katre N.V., Hirtzer P., Wolfe S.N., and Thomson J.W. Development of a lyophilized formulation of interleukin-2. Dev Biol Stand 74 (1992) 295-303 discussion 303-296
53. Thirumangalathu R., Krishnan S., Ricci M.S., Brems D.N., Randolph T.W., and Carpenter J.F. Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution. J Pharm Sci 98 (2009) 3167-3181
54. Jones L.S., Kaufmann A., and Middaugh C.R. Silicone oil induced aggregation of proteins. J Pharm Sci 94 (2005) 918-927
55. Locatelli F., Del Vecchio L., and Pozonni P. Pure red-cell aplasia "epidemic" - mystery completely revealed?. Perit Dial Int 27 (2007) S303-S307
56. Bee J.S., Nelson S.A., Freuns E., Carpenter J.F., and Randolph T.W. Precipitation of a monoclonal antibody by soluble tungsten. J Pharm Sci 98 (2009) 3290-3301. Recent paper that discusses how tungsten microparticles are introduced into prefilled syringes during the creation of the needle hole in the glass syringe. This work shows how and under what conditions these particles may cause protein aggregation and precipitation.
57. Andya J.D., Hsu C.C., and Shire S.J. Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS Pharmsci 5 (2003) E10. A case study that shows what type of analytical methods can be used to investigate routes of degradation in a freeze-dried MAb formulation. In particular, these studies showed that aggregation was caused by the formation of intermolecular disulphide linkages.
58. Avis K.E. Parenteral preparations. In: Gennaro A.R. (Ed). Remington's Pharmaceutical Sciences. edn 18 (1990), Mack Publishing Company 1545-1569
59. Rouan S.K.E. Biotechnology-based pharmaceuticals. In: Banker G.S., and Rhodes C.T. (Eds). Modern Pharmaceutics. edn 3 (1996), Marcel Dekker 843-873 [Swarbrick J (Series Editor): Drugs and the Pharmaceutical Sciences, vol 72.]
60. Poupitch G. Fluid bed drying in the laboratory. Am Biotechnol Lab 12 (1994) 30-34
61. Wildfong P.L., Samy A.S., Corfa J., Peck G.E., and Morris K.R. Accelerated fluid bed drying using NIR monitoring and phenomenological modeling: method assessment and formulation suitability. J Pharm Sci 91 (2002) 631-639
62. Miller D.P., Anderson R.E., and de Pablo J.J. Stabilization of lactate dehydrogenase following freeze thawing and vacuum-drying in the presence of trehalose and borate. Pharm Res 15 (1998) 1215-1221
63. Andya JD, Cleland JL, Hsu CC, Lam XM, Overcashier DE, Shire SJ, Yang JYF, Wu SSY: Protein formulation. US Patent March 14, 1996, US6267958 B1. This patent discusses the development of lyophilized formulations that after reconstitution by the end user are ready for subcutaneous (SC) injection at high protein concentration.
64. Gatlin L.A., and Gatlin C.A.B. Formulation and administration techniques to minimize injection pain and tissue damage associated with parenteral products. In: Gapta P.K., and Brazeau G.A. (Eds). Injectable Drug Development: Techniques to Reduce Pain and Irritation (1999), Interpharm Press 401-421
65. Zietkiewicz W., Kostrzewska E., and Gregor A. Tissue damage caused by parenteral injection of solutions of varying osmolality. Polski Tygodnik Lekarski 27 (1972) 869-870